GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

Ovarian Cancer Screening: Can Tests Detect It Early in Healthy Women?

CA-125 blood testing and transvaginal ultrasound can detect some ovarian cancers before symptoms, but routine screening has not been shown to lower ovarian cancer deaths in healthy women at average risk. The US Preventive Services Task Force therefore recommends against screening women without symptoms who are not known to have a high-risk hereditary cancer syndrome.[1]

What did the screening trial find?

UKCTOCS analyzed 202,562 postmenopausal women aged 50–74 in the UK; women with increased familial risk were excluded. The trial compared annual screening using CA-125 results tracked over time, with ultrasound when indicated, annual ultrasound alone, and no screening. After a median 16.3 years of follow-up, neither screening approach significantly reduced deaths from ovarian or fallopian tube cancer.[2]

Ovarian Cancer Screening: Can Tests Detect It Early in Healthy Women?
UKCTOCS: women included in the analysis and deaths from ovarian or fallopian tube cancer[2]
Group Women analyzed Cancer deaths
Annual CA-125-based screening 50,625 296
Annual ultrasound screening 50,623 291
No screening 101,314 619

In checking the published trial for this article, we compared the death counts with each group’s size: the no-screening group was about twice as large as either screened group, so the counts alone cannot show a benefit. The CA-125-based group had a 47.2% relative increase in the incidence of stage I ovarian or fallopian tube cancer versus no screening, but neither screening group had significantly fewer deaths from these cancers.[2] This is a review of published data, not firsthand clinical or patient experience.

Why not screen every healthy woman?

A false-positive result may lead a woman without cancer to have surgery.[1] Possible harms include infection, blood loss, bowel injury or unnecessary removal of an ovary.[3]

What does this mean in Japan?

The US recommendation is not a Japanese rule. Japan’s National Cancer Center says the country’s population-screening guidance does not include ovarian, fallopian tube or peritoneal cancer; people concerned about symptoms should seek medical care promptly.[4]

What if you have family risk or symptoms?

The US advice against routine screening does not cover women known to have a high-risk hereditary cancer syndrome.[1] If breast or ovarian cancer runs in your family, discuss inherited risk with a clinician. US guidance recommends a brief risk assessment for women with relevant personal or family history or ancestry, followed by genetic counseling if that assessment is positive; testing may then be appropriate.[5] This US pathway is not a statement of Japanese eligibility or screening frequency.

Persistent bloating, pelvic or abdominal pain, or changes in urination warrant medical assessment even if a previous test was normal: investigating symptoms is not routine screening of someone who feels well.[1] The US Centers for Disease Control and Prevention advises seeing a doctor if such symptoms are unusual for you and last two weeks or longer; unusual vaginal bleeding needs prompt attention.[6] A general health screening visit in Japan cannot replace assessment of persistent symptoms.

If you need help arranging an appointment in Japan or preparing records, the site’s contact team can discuss those practical steps. For symptoms, seek medical care rather than waiting for a message. Ask about visit logistics

Medical information only. This article has not received an article-specific physician review and is not a substitute for individual medical advice.

Sources

  1. US Preventive Services Task Force. Ovarian Cancer: Screening (2018).
  2. Menon U, et al. UKCTOCS long-term follow-up. Lancet (2021).
  3. National Cancer Institute. Ovarian, Fallopian Tube, and Primary Peritoneal Cancers Screening (PDQ), patient version.
  4. National Cancer Center Japan. Ovarian, Fallopian Tube and Peritoneal Cancer: Prevention and Screening (confirmed March 17, 2026; Japanese).
  5. US Preventive Services Task Force. BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing (2019).
  6. US Centers for Disease Control and Prevention. Symptoms of Ovarian Cancer (February 26, 2025).
Reviewed by GINZA Medical Coordination Team

Content is prepared for patient education and international consultation planning. It does not replace an individual diagnosis by a licensed physician.